Indolent Systemic Mastocytosis
NCI Definition: An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures. 
Indolent systemic mastocytosiss most frequently harbor alterations in NPM1 and IDH2 .
NPM1fs, IDH2 R140Q, IDH2 Mutation, IDH2 Exon 4 Mutation, and IDH2 Codon 140 Missense are the most common alterations in indolent systemic mastocytosis .
There is 1 clinical trial for indolent systemic mastocytosis, of which 1 is open and 0 are completed or closed. Of the trial that contains indolent systemic mastocytosis as an inclusion criterion, 1 is phase 2 (1 open).
Placebo and sarilumab are the most common interventions in indolent systemic mastocytosis clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.